About Jazz Pharmaceuticals plc - Ordinary Shares (JAZZ)
Jazz Pharmaceuticals Plc is a biopharmaceutical company that focuses on the development and commercialization of innovative treatments primarily in the areas of sleep medicine, neurology, and hematology. The company is dedicated to addressing significant unmet medical needs by creating therapies that improve patient outcomes and quality of life. Jazz Pharma's portfolio includes a range of pharmaceutical products designed to treat various conditions, with a particular emphasis on disorders related to sleep and central nervous system disorders. Through its research and development initiatives, the company aims to advance the scientific understanding of these conditions and contribute to the broader healthcare landscape. Read More
Jazz Pharmaceuticals (JAZZ) is a value stock with strong fundamentals, trading below industry averages in P/E and EV/EBITDA, while maintaining high profitability and steady growth potential.
Biopharma company Jazz Pharmaceuticals (NASDAQ:JAZZ) met Wall Street’s revenue expectations in Q2 CY2025, with sales up 2.1% year on year to $1.05 billion. The company’s outlook for the full year was close to analysts’ estimates with revenue guided to $4.23 billion at the midpoint. Its non-GAAP loss of $8.25 per share was 32.1% below analysts’ consensus estimates.
Jazz Pharmaceuticals Q2 2025 results miss revenue and EPS estimates, shares drop 6%. New CEO Renee Gala takes helm amid Xywav growth but investor concerns linger.
JAZZ Pharmaceuticals (NASDAQ:JAZZ) appears undervalued with strong profitability and decent growth, making it a candidate for value investors. Check the full analysis for details.
JAZZ Pharmaceuticals (NASDAQ:JAZZ) is an undervalued biopharma stock with strong profitability, reasonable financial health, and steady growth, making it a candidate for value investors.
Jazz Pharmaceuticals (NASDAQ:JAZZ) appears undervalued with strong profitability and reasonable growth, making it a potential pick for value investors.
Biopharma company Jazz Pharmaceuticals (NASDAQ:JAZZ) fell short of the market’s revenue expectations in Q1 CY2025, with sales flat year on year at $897.8 million. On the other hand, the company’s outlook for the full year was close to analysts’ estimates with revenue guided to $4.28 billion at the midpoint. Its non-GAAP profit of $1.68 per share was 63.9% below analysts’ consensus estimates.
As the Q1 earnings season wraps, let’s dig into this quarter’s best and worst performers in the pharmaceuticals industry, including Jazz Pharmaceuticals (NASDAQ:JAZZ) and its peers.
Biopharma company Jazz Pharmaceuticals (NASDAQ:JAZZ) fell short of the market’s revenue expectations in Q1 CY2025, with sales flat year on year at $897.8 million. On the other hand, the company’s outlook for the full year was close to analysts’ estimates with revenue guided to $4.28 billion at the midpoint. Its non-GAAP profit of $1.68 per share was 63.9% below analysts’ consensus estimates.
When you look at JAZZ PHARMACEUTICALS PLC (NASDAQ:JAZZ), it's hard to ignore the strong fundamentals, especially considering its likely undervaluation.
